摘要
为探讨人附睾蛋白4(HE4)在子宫内膜癌中的表达及临床意义,采用酶联免疫吸附试验(ELISA)对66例子宫内膜癌、12例子宫内膜不典型增生、37例子宫良性肿瘤以及36例健康对照者血清HE4浓度进行检测分析,并对其中11例子宫内膜癌患者进行术后随访。结果发现子宫内膜癌患者血清HE4水平高于健康对照和子宫良性肿瘤,差异有统计学意义(P<0.05);HE4在子宫内膜癌患者血清中的表达水平随分期呈上升趋势,差异有统计学意义(χ2=11.89,P<0.05);子宫内膜癌患者术后血清中HE4的表达水平明显低于术前(P<0.01)。HE4可作为子宫内膜癌血清学标志物,是对子宫内膜癌作早期辅助诊断的客观指标,有助于了解疾病进展和预后评估。
To investigate the expression of human epididymis protein 4（HE4） in the serum of patients with endometrial cancer and its relative clinical significance, the serum levels of HE4 in 66 cases with endometrial cancer, 12 cases with endometrial atypical hyperplasia, 37 cases with uterus benign tumor and 36 cases of healthy control were determined. In addition, 11 followup cases after endometrial cancer surgical resection was measured by enzyme-linked immunosorbent assay（ELISA）. The results showed that, the concentration of HE4 was higher in the serum of patients with endometrial cancer, compared with healthy controls and patients with benign tumor（P〈0.05） ; the expression of HE4 in endometrial cancer increased with the stage progression with statistical significance（x^2= 11.89,P〈0.01）; HE4 concentration in the serum was obviously lower after surgical resection, compared with that before operation（P〈0.01）. HE4 may act as a serum marker for endometrial cancer, and useful for diagnosis, and evaluation of disease progression and prognosis.
出处
《现代免疫学》
CAS
CSCD
北大核心
2012年第2期164-167,共4页
Current Immunology
基金
上海市卫生局青年基金(2008Y114)
